Compare LSBK & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSBK | DTIL |
|---|---|---|
| Founded | 1891 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.0M | 97.7M |
| IPO Year | 2006 | 2019 |
| Metric | LSBK | DTIL |
|---|---|---|
| Price | $15.43 | $3.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 4.5K | ★ 200.6K |
| Earning Date | 01-21-2026 | 03-25-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | ★ 10.59 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $28,018,000.00 | $698,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.30 |
| P/E Ratio | $15.91 | ★ N/A |
| Revenue Growth | ★ 8.40 | N/A |
| 52 Week Low | $11.50 | $3.53 |
| 52 Week High | $16.95 | $8.82 |
| Indicator | LSBK | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 34.15 |
| Support Level | $15.26 | $3.53 |
| Resistance Level | $15.74 | $4.10 |
| Average True Range (ATR) | 0.24 | 0.25 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 50.00 | 7.41 |
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.